Fiduciary Family Office’s Biogen BIIB Stock Holding History

Fiduciary Family Office’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,172	Closed	-$303K	–	217
2023 Q4	$303K	Buy	+1,172	New	+$288K	0.13%	164

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fiduciary Family Office's BIIB Position: Q1 2024 in Review

Fiduciary Family Office sold out of Biogen (BIIB) in Q1 2024, closing a stake of 1,172 shares — an estimated $303K sold.

Fiduciary Family Office first reported a position in BIIB in Q4 2023 and held it in 1 quarter. The position peaked at $303K in Q4 2023. 954 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

Fiduciary Family Office reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
Fiduciary Family Office sold 1,172 Biogen shares in Q1 2024, an estimated $303K.
Fiduciary Family Office first reported a position in Biogen in Q4 2023 and held it in 1 quarter.
Fiduciary Family Office's Biogen position peaked at $303K in Q4 2023.
954 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on Fiduciary Family Office's 13F filing for Q1 2024, filed 7 May 2024.